We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

146 hedge funds and large institutions have $869M invested in Enanta Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 57 increasing their positions, 49 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,897% more call options, than puts

Call options by funds: $10.6M | Put options by funds: $176K

16% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 49

2.64% less ownership

Funds ownership: 95.08% → 92.44% (-2.6%)

8% less funds holding

Funds holding: 159 → 146 (-13)

15% less capital invested

Capital invested by funds: $1.02B → $869M (-$153M)

55% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 22

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
146
Holders Change
-13
Holders Change %
-8.18%
% of All Funds
2.35%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
10
Increased
57
Reduced
49
Closed
22
Calls
$10.6M
Puts
$176K
Net Calls
+$10.4M
Net Calls Change
-$94K

Top Buyers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
+$12.2M
2
State Street
State Street
Massachusetts
+$6.14M
3
BlackRock
BlackRock
New York
+$6.03M
4
CC
Commodore Capital
New York
+$5.47M
5
CCM
Camber Capital Management
Massachusetts
+$5.01M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$46.5M
2
FFM
Fairmount Funds Management
Pennsylvania
-$24.3M
3
Invesco
Invesco
Georgia
-$11.4M
4
Northern Trust
Northern Trust
Illinois
-$3.71M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$175M +$6.03M +132,329 +4%
AC
2
Armistice Capital
New York
$96.7M +$274K +6,000 +0.3%
FCM
3
Farallon Capital Management
California
$72.1M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$70.8M +$2.06M +45,279 +3%
State Street
5
State Street
Massachusetts
$70.3M +$6.14M +134,775 +10%
Northern Trust
6
Northern Trust
Illinois
$41.1M -$3.71M -81,277 -8%
KAM
7
Krensavage Asset Management
New York
$27.7M +$249K +5,458 +0.9%
Renaissance Technologies
8
Renaissance Technologies
New York
$22M +$237K +5,200 +1%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$17.6M +$728K +15,960 +4%
Jacobs Levy Equity Management
10
Jacobs Levy Equity Management
New Jersey
$16.2M -$148K -3,245 -0.9%
B
11
Braidwell
Connecticut
$15.2M +$14.9M +325,838 New
UBS AM
12
UBS AM
Illinois
$13.7M +$12.2M +266,993 +983%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$12.3M -$2.09M -45,952 -15%
First Manhattan
14
First Manhattan
New York
$11.3M – – –
Goldman Sachs
15
Goldman Sachs
New York
$11M +$2.77M +60,851 +35%
Norges Bank
16
Norges Bank
Norway
$10.5M +$3.04M +66,600 +42%
CC
17
Commodore Capital
New York
$10.4M +$5.47M +120,000 +116%
TCM
18
Tang Capital Management
California
$9.3M +$2.84M +62,300 +45%
JP Morgan Chase
19
JP Morgan Chase
New York
$8.45M +$406K +8,916 +5%
T. Rowe Price Associates
20
T. Rowe Price Associates
Maryland
$8.11M -$3.03M -66,384 -28%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$7.83M -$263K -5,760 -3%
Charles Schwab
22
Charles Schwab
California
$6.79M +$172K +3,783 +3%
Morgan Stanley
23
Morgan Stanley
New York
$6.44M -$1.97M -43,149 -24%
SCM
24
Soleus Capital Management
Connecticut
$6.41M +$675K +14,800 +12%
Principal Financial Group
25
Principal Financial Group
Iowa
$5.69M -$233K -5,117 -4%
1
2 3 4 5

ENTA Hedge Fund Activity: Q4 2022 in Review

146 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2022, worth a combined $869M — down 15% from $1.02B a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of ENTA and 10 opened new positions — a net loss of 12 holders — while 49 trimmed existing stakes and 57 added.

The largest buyer was UBS AM, adding an estimated $12.2M. The largest seller was RA Capital Management, exiting entirely with an estimated $46.5M sold.

  • 146 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2022, down from 159 in Q3 2022.
  • Funds reported $869M of Enanta Pharmaceuticals stock for Q4 2022, down 15% quarter-over-quarter.
  • 10 funds opened new Enanta Pharmaceuticals positions in Q4 2022 and 22 closed out, a net change of -12 holders.
  • The largest Enanta Pharmaceuticals buyer in Q4 2022 was UBS AM, an estimated $12.2M added.
  • The largest Enanta Pharmaceuticals seller in Q4 2022 was RA Capital Management, an estimated $46.5M sold.

Based on aggregated 13F filings for Q4 2022.